U.S. Markets open in 1 hr 2 mins

Innovus Pharma Reports New Quarterly Revenue Record of $7.3 million for the Second Quarter 2018 and Expands to Canadian Market

SAN DIEGO--(BUSINESS WIRE)--

Beyond Human™ Sales & Marketing Strategy Results in 258.7% Net Revenue Growth Compared to Same Period in 2017

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (INNV), today reported results for the second quarter 2018.

Notable selected highlights from the Second Quarter of 2018

  • Revenues of $7.3 million, up 259% year-over-year and 61% from prior quarter.
  • Gross margin remains consistent at 81% from prior quarter.
  • Net loss remains consistent at $1.8 million from prior quarter even with significant investment in marketing and 61% increase in net revenues from prior quarter.
  • Monthly subscription revenue increases 25% to $258,000.
  • General and Administrative expenses declined to 26% as a percentage of sales compared to 58% in the prior year second quarter and 37% in the previous quarter.
  • Fourth straight quarter of revenue growth.
  • Added four products: Apeaz®, Androferti®, UriVarx® and ProstaGorx® to two large US and Canadian retail chains.
  • Successfully expanded our Beyond Human™ sales and marketing platform to Canada representing 14.3% of total net sales.
  • Expanded our Beyond Human™ sales and marketing platform to direct mail including slim jim brochures, retention postcards, fulfillment cross ordered pieces and tear-sheets resulting in 84% of total net sales.
  • Received approval to expand our Amazon® e-commerce store to five main markets in Europe (France, UK, Germany, Italy and Spain).
  • Received update from our Fluticare® initial partner that they expect FDA approval of the ANDA in Q4 2018.
  • Engaged in licensing discussions for exclusive U.S. and Canada rights to a U.S. Abbreviated OTC New Drug Application and the equivalent Canadian dossier for Tadalafil (sold under the trademark Cialis® in the US) for a potential switch to OTC by the FDA. The Cialis® trademark is owned by Eli Lilly and Company.
  • Completed build-out of internally managed fulfillment center.

“We continue to execute on our plan towards our path to profitability. This is the second quarter where our revenues came out higher than our original guidance range, a testament to the strength of our sales and marketing efforts and our deep and unique portfolio of products. The relentless effort by the Company to continue its growth resulted in second quarter net revenues of $7.3 million, another record quarter for the Company,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.

“We now have a proven business model allowing us to continuously add new products and expand into new countries, while benefiting from the scale of efficiencies to reduce our cost of doing business to continue towards our goal of profitability. I am thrilled and looking forward to updating our shareholders on our earnings call on more details and on our upcoming expected successes. On the basis of this quarterly net revenues and for the first six months of 2018, our net revenue is $11.9 million, which is already $3 million more than what the Company achieved for the entirety of 2017. Thus, we are increasing our current annual net revenue guidance for 2018 to $23 million,” continued Dr. Damaj.

The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT today to discuss the financial results and recent business developments. To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers. Participant Elite Entry Number: 0561047. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Replay Access Code: 10123041. The replay will be available shortly after the end of the conference call.

 
Consolidated Statements of Operations
   
Three months ended
June 30,
2018   2017  
(unaudited)
Net revenue:
Product sales, net $6,970,312 $2,031,157
License revenue 2,577 7,500
Service revenue 155,648 -
Cooperative marketing revenue 183,636   -  
Total net revenue 7,312,173   2,038,657  
 
Operating expense:
Cost of product sales 1,338,950 408,579
Research and development 22,605 15,063
Sales and marketing 5,528,886 1,555,736
General and administrative 1,919,301   1,185,435  
Total operating expense 8,809,742   3,164,813  
 
Loss from operations (1,497,569 ) (1,126,156 )
 
 
Other income and (expense):
Interest expense (325,982 ) (110,130 )
Loss on extinguishment of debt (38,587 ) -
Other income (expense), net 266 (206 )
Fair value adjustment for contingent consideration 21,644 98,979
Change in fair value of derivative liabilities -   3,463  
Total other expense, net (342,659 ) (7,894 )
 
Net loss (1,840,228 ) (1,134,050 )
 
 
Net loss per share of common stock – basic and diluted:

$(0.01

)

 

$(0.01

)

 
Weighted average number of shares of common stock outstanding – basic and diluted

205,106,912

 

159,997,395

 
 
 
Consolidated Statements of Operations
 
Six months ended
June 30,
2018   2017  
(unaudited)
Net revenue:
Product sales, net $11,512,338 $4,208,447
License revenue 5,155 7,500
Service revenue 155,648 -
Cooperative marketing revenue 183,636   -  
Total net revenue 11,856,777   4,215,947  
 
Operating expense:
Cost of product sales 2,203,045 849,055
Research and development 33,892 18,246
Sales and marketing 8,830,670 3,243,087
General and administrative 3,615,322   2,889,098  
Total operating expense 14,682,929   6,999,486  
 
Loss from operations (2,826,152 ) (2,783,539 )
 
 
Other income and (expense):
Interest expense (567,870 ) (667,609 )
Loss on extinguishment of debt (294,272 ) (304,828 )
Other income (expense), net 375 (822 )
Fair value adjustment for contingent consideration 18,799 126,154
Change in fair value of derivative liabilities -   (48,193 )
Total other expense, net (842,968 ) (895,298 )
 
Net loss (3,669,120 ) (3,679,837 )
 
 
Net loss per share of common stock – basic and diluted:

$(0.02

)

 

$(0.02

)

 
Weighted average number of shares of common stock outstanding – basic and diluted

196,070,469

 

147,617,064

 
 
 

Condensed Consolidated Balance Sheet Data

 
June 30, 2018

1

Assets
Cash $1,614,495
Accounts receivable, net 287,350
Prepaid expenses and other current assets 693,930
Inventories 2,229,183
Intangible assets and other non-current assets 5,110,277
Total assets $9,935,235
Liabilities & Stockholders' Equity
Accounts payable & accrued liabilities $3,262,213
Total accrued compensation 1,973,449
Deferred revenue and customer deposits 97,950
Accrued interest payable 22,168
Short-term loans payable 132,197

 

Notes payable and non-convertible debenture, net of discount 1,816,396
Total contingent consideration 1,460,203
Total stockholders' equity 1,170,659
Total liabilities & stockholders' equity $9,935,235

1 The Condensed Consolidated Balance Sheet Data has been derived from the audited consolidated financial statements as of that date.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its financial results, projected revenues, projected online subscribers and other customers, estimated markets for its products, and statements about achieving its other corporate and business development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180814005691/en/

  • Cannabis Goes Legal in Canada as Investors Ride Stocks Higher
    Business
    Bloomberg

    Cannabis Goes Legal in Canada as Investors Ride Stocks Higher

    Stores in St. John’s, Newfoundland are set to be the first to sell recreational cannabis, with some planning to open at 12:01 a.m. local time, followed by more than 100 outlets and websites opening across the country of 37 million people. “The eyes of the world are on are Canada and Canadians should feel very proud, because people have been fighting for decades to make this moment a reality,” said Brendan Kennedy, chief executive officer of Tilray Inc., the largest cannabis company by market value. Canada is the second country in the world to legalize recreational pot nationally after Uruguay.

  • Steven Mnuchin, Who Sat on Sears' Board for Years, Could Impact the Pensions of Thousands of Workers
    Business
    Fortune

    Steven Mnuchin, Who Sat on Sears' Board for Years, Could Impact the Pensions of Thousands of Workers

    Long before he was Secretary of the Treasury, Steven Mnuchin was a student at Yale University. One of those was Eddie Lampert. Lampert, of course, is the recently departed CEO of Sears Holdings, which filed for Chapter 11 bankruptcy Monday.

  • 7 Stocks to Buy and Hold Through Any Market Selloff
    Business
    InvestorPlace

    7 Stocks to Buy and Hold Through Any Market Selloff

    Last week’s market collapse made headlines throughout the world. Since the sharp correction has negatively impacted virtually all investment sectors, you’re going to find discounted deals everywhere you look.

  • Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves
    Business
    MarketWatch

    Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves

    After two consecutive quarters of missing the mark on its own forecasts for subscriber growth, Netflix Inc. hopes to put an end to the big swings in its stock with some changes in its accounting. In kicking off tech’s earnings season Tuesday, Netflix (NFLX) reported better-than-expected subscriber growth in the quarter, leading to an 11% jump in its shares in after-hours trading. Three months ago, Netflix reported weaker-than-expected subscriber growth, sending its stock tumbling around 12% in the next trading day.

  • General Electric (GE) Stock Sinks As Market Gains: What You Should Know
    Finance
    Zacks

    General Electric (GE) Stock Sinks As Market Gains: What You Should Know

    With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

  • Boeing delivers first 737 Max 8 BBJ and unveils Max 7 luxury interior (Photos)
    Business
    American City Business Journals

    Boeing delivers first 737 Max 8 BBJ and unveils Max 7 luxury interior (Photos)

    Boeing has delivered its very first 737 Max 8 business jet to a paying customer. It's the first of 20 BBJ Max jets that buyers from around the world have ordered from the Chicago-based jetmaker since they went on sale. Boeing spokesman Dmitry Krol declined to identify the buyer of the jet, which is the second of its kind made at Boeing's Renton 737 factory.

  • Social Security Checks Are Increasing: What Does That Mean For You?
    Business
    Fortune

    Social Security Checks Are Increasing: What Does That Mean For You?

    Social Security checks will see their biggest increase in four years as 2019 kicks off. The Social Security Administration has approved a 2.8% cost of living adjustment (COLA) for next year. That follows a 2% jump this year and an increase of just

  • These are the bad things about early retirement that no one talks about
    News
    MarketWatch

    These are the bad things about early retirement that no one talks about

    For all the glamour of living an early retirement lifestyle, there are plenty of negatives I’ve come to discover since I permanently left my job in 2012. As a result, you’re repeatedly forced to will yourself into action.

  • Cannabis might be most disruptive force since Amazon for ...
    Business
    CNBC Videos

    Cannabis might be most disruptive force since Amazon for ...

    Jim Cramer surveys the pot craze as Canada prepares to legalize cannabis nationwide and flags the companies he thinks will be long-term winners.

  • 3 Stocks for Warren Buffett Fans
    Business
    Motley Fool

    3 Stocks for Warren Buffett Fans

    Warren Buffett has no shortage of acolytes, and it's easy to see why. The Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) chief and founder has made thousands of early investors in his conglomerate rich as the parent of businesses like GEICO car insurance and Burlington Northern Santa Fe railroad has posted average annual returns of 20% over the last 50 years, crushing the market. Buffett has never gotten too big for his britches, however.

  • Analysts Give Philip Morris a ‘Buy’ Rating before Its Q3 Earnings
    Business
    Market Realist

    Analysts Give Philip Morris a ‘Buy’ Rating before Its Q3 Earnings

    Can Philip Morris Outperform Analysts’ Expectations in Q3 2018? Of the 19 analysts that follow Philip Morris International (PM), 52.6% recommend a “buy,” 42.1% recommend a “hold,” and 5.3% recommend a “sell.” On average, analysts have set a price target of $91.69, which represents a potential return of 11.4% from its current stock price of $82.31. Berenberg cut PM’s target price from $85.00 to $84.00 on October 1.

  • Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla
    Business
    MarketWatch

    Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla

    The following article is part of a package of stories that MarketWatch is publishing to mark the start of full legalization of cannabis for adult use in Canada on Wednesday. Smith Falls, Ontario–based Canopy Growth Corp. made headlines and drove cannabis stocks to new heights over the summer when it announced that Corona brewer Constellation Brands Inc. was going to invest an additional $4 billion in the company. Billed by both companies as a strategic partnership, the additional $4 billion investment adds to the 9.9% stake that Constellation bought in October of last year and sets the company up to either be bought outright by Constellation — via warrants that could increase its stake to more than 50% — or continue to work with the beverage company to create a range of consumer-focused cannabis products that may one day appear in markets in dozens of countries.

  • Why MannKind Corp. Soared 16.4% Tuesday
    Business
    Motley Fool

    Why MannKind Corp. Soared 16.4% Tuesday

    After MannKind Corp. (NASDAQ: MNKD) announced that it closed on its planned collaboration agreement with United Therapeutics (NASDAQ: UTHR), its shares rallied 16.4% on Tuesday. MannKind only has one Food and Drug Administration (FDA)-approved drug to its name, Afrezza, an inhalable insulin. Afrezza was launched in 2015 and sales have been far shy of optimistic pre-launch forecasts.

  • Where Will NVIDIA Be in 5 Years?
    Business
    Motley Fool

    Where Will NVIDIA Be in 5 Years?

    At one time, NVIDIA (NASDAQ: NVDA) floated under the radar in the technology sector. Its graphics processing units (GPUs) were then niche tech products that appealed mainly to graphic artists and hardcore PC gamers, but that all changed over the last

  • Marijuana Stocks to Watch in October -- and Into 2019
    Business
    Motley Fool

    Marijuana Stocks to Watch in October -- and Into 2019

    Tomorrow, Wednesday, Oct. 17, Canada will become the first industrialized county in the world where marijuana is legal for adult recreational use -- and only the second country, along with Uruguay, where such use is legal.  Not only does this open up

  • Price Target Update for Canopy Growth in October
    Business
    Market Realist

    Price Target Update for Canopy Growth in October

    How Analysts Rate These Cannabis Stocks in October (Continued from Prior Part) Canopy Growth Without a doubt, Canopy Growth (CGC)(WEED) has been one of the hottest cannabis stocks on the market (MJ). The company is one of the most valuable companies,

  • A Look at AT&T’s Dividends
    Business
    Market Realist

    A Look at AT&T’s Dividends

    What Investors Should Know about AT&T’s Growth Prospects (Continued from Prior Part) Shareholder returns Increasing capital returns to shareholders is one of AT&T’s (T) main priorities. In the second quarter, the company returned $3.1 billion to shareholders

  • Call of the day: Tilray as Benchmark starts coverage with bullish rating
    Business
    Yahoo Finance Video

    Call of the day: Tilray as Benchmark starts coverage with bullish rating

    Benchmark initiated its coverage of Tilray with a 'buy' rating and a $200 price target. Analyst Mike Hickey said he's bullish on the cannabis company's early leadership in the medical cannabis market in Canada and its strategic alliance with Novartis.

  • Walmart is aggressively shifting away from its most legendary shopping format
    Finance
    Yahoo Finance

    Walmart is aggressively shifting away from its most legendary shopping format

    Walmart (WMT) continues to kill off the American shopping creation it’s most known for, the massive supercenter that sells everything under one roof. With the U.S. market already having more than 3,500 Walmart supercenters and a focus by CEO Doug McMillon to increase spending on eCommerce and India, Walmart said Tuesday it will open a mere 10 supercenters in 2019. The company has reduced emphasis on the store format pioneered by founder Sam Walton – which could average a gargantuan 178,000 square feet – in recent years.

  • 3 Marijuana Stocks to Buy in October
    Business
    Motley Fool

    3 Marijuana Stocks to Buy in October

    If you've been trading marijuana stocks hoping to make a lot of money fast, stop it. Three that I think fit the bill are CannaRoyalty (NASDAQOTH: CNNRF), Canopy Growth (NYSE: CGC), and Scotts Miracle-Gro (NYSE: SMG). Here's why these look like great marijuana stocks to buy in October.

  • Business
    InvestorPlace

    30 Marijuana Stocks to Buy as the Future Turns Green

    With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible. For instance, some of the top marijuana stocks are levered toward medical cannabis.

  • The Largest Private Employer in the World May Soon Sell Marijuana Products
    Business
    Motley Fool

    The Largest Private Employer in the World May Soon Sell Marijuana Products

    With literally hours remaining, Canada is set to lift the curtain on nine decades of recreational marijuana prohibition tomorrow. This makes Canada the first industrialized country in the world to legalize adult-use weed. As you might rightly imagine, investors can't wait for this legalization to take place.

  • Johnson & Johnson Reports Strong Q3 Results, Stock Rises
    Business
    Market Realist

    Johnson & Johnson Reports Strong Q3 Results, Stock Rises

    Johnson & Johnson Reports Strong Q3 Results, Stock Rises Johnson & Johnson’s third-quarter earnings Johnson & Johnson (JNJ) reported its third-quarter earnings results before the market opened today. It reported sales of $20.3 billion, up ~3.6% YoY (

  • Finance
    CNBC

    Disney vs Netflix: Here's which stock would have made you richer if you invested $1,000 10 years ago

    On October 16, 1923, Walt and Roy Disney founded The Walt Disney Company and, nearly a century later, the company is one of the largest and most successful media conglomerates in the world. The answer is Netflix. According to CNBC calculations, a $1,000 investment in Netflix in October 2008 would be worth more than $97,560 as of after the earning bell on Monday, or more than 96 times as much, including price appreciation and dividends reinvested.

  • Netflix user growth beats expectations, shares spike
    Finance
    Yahoo Finance

    Netflix user growth beats expectations, shares spike

    Netflix (NFLX) reported quarterly user growth that exceeded Wall Street expectations. The company issued guidance that it would add 9.4 million new members in the fourth quarter of 2018. Netflix’s stock rose 10.77% to $383.70 per share at 7:29 a.m. Wednesday.